Your browser doesn't support javascript.
loading
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Raghu, Ganesh; Brown, Kevin K; Collard, Harold R; Cottin, Vincent; Gibson, Kevin F; Kaner, Robert J; Lederer, David J; Martinez, Fernando J; Noble, Paul W; Song, Jin Woo; Wells, Athol U; Whelan, Timothy P M; Wuyts, Wim; Moreau, Emmanuel; Patterson, Scott D; Smith, Victoria; Bayly, Selina; Chien, Jason W; Gong, Qi; Zhang, Jenny J; O'Riordan, Thomas G.
Afiliación
  • Raghu G; Center for Interstitial Lung Diseases, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: graghu@u.washington.edu.
  • Brown KK; Division of Pulmonary and Critical Care Medicine, National Jewish Medical Center, Denver, CO, USA.
  • Collard HR; Department of Medicine, University of California San Francisco at San Francisco, CA, USA.
  • Cottin V; University of Lyon, Lyon, France.
  • Gibson KF; University of Pittsburgh, Pittsburgh, PA, USA.
  • Kaner RJ; Department of Clinical Medicine and Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Lederer DJ; Division of Pulmonary, Allergy and Critical Care, Columbia University Medical Center, New York, NY, USA.
  • Martinez FJ; Department of Medicine, Cornell University, New York, NY, USA.
  • Noble PW; Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
  • Song JW; Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
  • Wells AU; Department of Medicine, National Heart & Lung Institute, Royal Brompton Hospital, Imperial College, London, UK.
  • Whelan TP; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA.
  • Wuyts W; Unit for Interstitial Lung Diseases, University of Leuven, Leuven, Belgium.
  • Moreau E; Research and Development, bioMerieux, Lyon, France.
  • Patterson SD; Clinical Research, Gilead Sciences, Seattle, WA, USA.
  • Smith V; Clinical Research, Gilead Sciences, Seattle, WA, USA.
  • Bayly S; Clinical Research, Gilead Sciences, Seattle, WA, USA.
  • Chien JW; Clinical Research, Gilead Sciences, Seattle, WA, USA.
  • Gong Q; Clinical Research, Gilead Sciences, Seattle, WA, USA.
  • Zhang JJ; Clinical Research, Gilead Sciences, Seattle, WA, USA.
  • O'Riordan TG; Clinical Research, Gilead Sciences, Seattle, WA, USA.
Lancet Respir Med ; 5(1): 22-32, 2017 01.
Article en En | MEDLINE | ID: mdl-27939076
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores Enzimáticos / Fibrosis Pulmonar Idiopática / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores Enzimáticos / Fibrosis Pulmonar Idiopática / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido